Updated Data With Larotrectinib in TRK Fusion-Positive Solid Tumors скачать в хорошем качестве

Updated Data With Larotrectinib in TRK Fusion-Positive Solid Tumors

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated data with larotrectinib (Vitrakvi) in TRK fusion-positive solid tumors at the ESMO Congress 2019.  The tumor-agnostic TRK inhibitor larotrectinib showed sustained antitumor activity in adult and pediatric patients with TRK fusion–positive cancers, based on updated findings from an integrated analysis of an adult phase I trial, the phase I/II SCOUT pediatric trial, and the phase II adult/adolescent NAVIGATE basket trial. The drug induced an objective response rate (ORR) of 79% among 153 evaluable patients with various tumor types. Notably, the ORR consisted of 24 complete responses and 97 partial responses. Another 12% of patients had stable disease as their best response, translating to a 91% clinical benefit rate. Among 108 patients with confirmed responses, the median duration of response was 35.2 months. Moreover, median progression-free survival surpassed 2 years at 25.9 months, says Hong. For more resources and information from the ESMO Congress 2019: https://www.targetedonc.com/conferenc...